Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30863409 | 1.00 | HTT (0.37) | HTTKMT2AATRPLA2G1BATG4B | |
| SCHEMBL15306524 | 0.80 | HTT (0.35) | HTTKMT2AATRGRM5MAPK1 | |
| SCHEMBL20839189 | 0.76 | KDM4E (0.32) | KDM4EUSP7 | |
| SCHEMBL15065749 | 0.76 | HSP90AA1 (0.39) | KDM4EGRM5 | |
| SCHEMBL17375392 | 0.76 | CDK2 (0.37) | KDM4EGRM5 | |
| SCHEMBL3134237 | 0.72 | ADORA2A (0.46) | HTTKMT2AKDM4EMBOAT4 | |
| SCHEMBL165172 | 0.72 | — | — | |
| SCHEMBL29912802 | 0.72 | — | — | |
| SCHEMBL15917590 | 0.71 | — | — | |
| SCHEMBL31709840 | 0.71 | KDM4E (0.33) | HTTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388553-A1 | AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS | INCYTE CORP (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250313550-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2025-10-09 | — | — | US | disclosed |
| US-12421197-B2 | Aminopyrazine derivatives as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2025-09-23 | — | — | US | disclosed |
| US-12365668-B2 | Aminopyrazine diol compounds as PI3K-y inhibitors | INCYTE CORPORATION (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240400541-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2024-12-05 | — | — | US | disclosed |
| CN-118290402-A | Aminopyrazine diol compounds as PI 3K-gamma inhibitors | 因赛特公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| CN-112074505-B | Aminopyrazine diol compounds as PI 3K-gamma inhibitors | 因赛特公司 | 2024-04-05 | — | — | CN | disclosed |
| US-11926616-B2 | Aminopyrazine diol compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| US-8658661-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-25 | — | — | US | disclosed |
| WO-2013113799-A1 | PHENYL -C-OXADIAZOLE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE PRODUCTION COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-08 | — | — | WO | disclosed |
| WO-2013113799-A1 | PHENYL -C-OXADIAZOLE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE PRODUCTION COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-08 | — | — | WO | disclosed |
| US-20130195879-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| EP-2606045-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | Boehringer Ingelheim International GmbH (DE) | 2013-06-26 | — | — | EP | disclosed |
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
| WO-2012024150-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024150-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421197-B2 | Aminopyrazine derivatives as PI3K-γ inhibitors | PIK3R5, PIK3CD, PIK3CG | HTT 1262/4885KMT2A 2553/4885ATR 500/4885 |
| US-20240400541-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | PIK3CD, PIK3R5, PIK3CG | HTT 1840/4885KMT2A 2242/4885ATR 452/4885 |
| US-20250388553-A1 | AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3C2B | HTT 623/4885KMT2A 2356/4885ATR 861/4885 |
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | HTT 2627/4885KMT2A 2250/4885ATR 737/4885 |
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | HTT 4331/4885KMT2A 4486/4885ATR 4549/4885 |
| US-11926616-B2 | Aminopyrazine diol compounds as PI3K-γ inhibitors | PIK3CD, PIK3R5, PIK3CG | HTT 1717/4885KMT2A 2796/4885ATR 352/4885 |
| US-12365668-B2 | Aminopyrazine diol compounds as PI3K-y inhibitors | PIK3CD, PIK3R5, PIK3CG | HTT 1840/4885KMT2A 2242/4885ATR 452/4885 |
| US-20130195879-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | LTB4R, LTB4R2, LTC4S | HTT 4495/4885KMT2A 4343/4885ATR 4408/4885 |
| US-20250313550-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | PIK3CD, PIK3R5, PIK3CG | HTT 1840/4885KMT2A 2242/4885ATR 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.